Cardiovascular disease (CVD) is responsible for significant morbidity and premature mortality in Australia. Ischaemic heart disease was the leading cause of death in 2020 and cerebrovascular disease was the third most common cause of death.
As the first major update to Australian CVD risk assessment guidelines in over a decade, the 2023 Australian Guideline for assessing and managing cardiovascular disease risk and associated Aus CVD Risk Calculator reflect the latest evidence on assessing, communicating, and managing CVD risk. Developed using Australian-specific data and the latest evidence, it supersedes the 2012 Guidelines for the management of absolute cardiovascular disease risk.
New cardiovascular disease (CVD) Risk Guidelines were commissioned by the Australian Government Department of Health and Aged Care, and developed by the Heart Foundation on behalf of the Australian Chronic Disease Prevention Alliance (ACDPA) (Diabetes Australia, Kidney Health Australia and Stroke Foundation). The guideline has been endorsed by the Royal Australian College of General Practitioners (RACGP).
The new guideline has been developed according to the processes and standards outlined in the 2016 Australian National Health and Medical Research Council’s (NHMRC) Guidelines for Guidelines.
The guideline was developed under the direction and governance of nine expert advisory groups with multidisciplinary clinical and consumer input (see Appendix 1). Expertise was sourced across the disciplines of cardiology, general practice, nephrology, neurology, endocrinology, stroke care, epidemiology, Indigenous health, nutrition, behavioural science, nursing and pharmacy. Special attention was given to First Nations people’s health, and the Indigenous Health Expert Subgroup advised on every aspect of the guideline development.
The project aim was to develop an updated CVD Risk clinical guideline and corresponding CVD risk prediction algorithm enabling best practice assessment and management of CVD risk, overseen by the Guideline Advisory Group which consists of representatives from the ACDPA.
An individual’s risk of developing CVD depends on the combined effect of multiple risk factors. Risk assessment, therefore, remains fundamental to the early detection and prevention of CVD. The guideline encourages early modification of CVD risk factors, helps target medicines to those who will benefit most, and informs clinical decision-making.
The guideline and calculator help healthcare professionals assess, communicate and manage a person’s risk of developing cardiovascular disease. Australian Health Journal spoke with cardiologist and Heart Foundation Chief Medical Advisor, Professor Garry Jennings AO on how HCPs in primary health care can use the resources, guideline and risk calculator in clinical practice.
You Might also like
-
Implementing improvements in referral management and demand
Nalani Cox joined Gold Coast Health in 2019 as a Nurse Manager focused on improving referral management processes within the outpatient environment through the implementation of the Clinical Prioritisation Criteria. This work became a focus point for the organisation in 2020 when Nalani led an organisational wide change project introducing Smart Referrals, Refer Your Patient website and HealthPathways which has culminated in her position as the ADON of the Referral Strategy and Performance Department.
-
Australian Healthcare Week
Held 27th-28th March at the ICC Sydney, the expo is one of the largest, if not the largest healthcare events in the regions. AHJ as media partner attended and met with delegates, exhibitors and leaders in the healthcare industry. Click the post to see footage.
-
Developing the next generation of medicines to target and enhance the microbiome
Australian Health Journal spoke to Associate Professor Sam Forster, Research Group Head
Microbiota and Systems Biology, Hudson Institute of Medical Research, Team Leader, Australian Microbiome Culture Collection & Chief Scientific Officer, BiomeBank and Dr Sam Costello, Co-Founder and CEO of BiomeBank about the microbiome, partnering and some of the breakthroughs in recent years.